| 陈书悦,查伟锋,周梦云,等.青蒿汤加减方对慢性光化性皮炎患者T细胞亚群及细胞因子水平的影响[J].浙江中医药大学学报,2023,47(4):410-415. |
| 青蒿汤加减方对慢性光化性皮炎患者T细胞亚群及细胞因子水平的影响 |
| Effects of Modified Qinghao Decoction on T Cell Subsets and Cytokine Levels in Patients with Chronic Actinic Dermatitis |
| DOI：10.16466/j.issn1005-5509.2023.04.014 |
| 中文关键词: 青蒿汤加减方 慢性光化性皮炎 临床疗效 T细胞亚群 细胞因子 免疫调节 |
| 英文关键词: modified Qinghao Decoction chronic actinic dermatitis clinical efficacy T cell subsets cytokines immunomodulatory |
| 基金项目:杭州市医药卫生科技项目(A20200079) |
|
| 摘要点击次数: 665 |
| 全文下载次数: 396 |
| 中文摘要: |
| [目的] 探究青蒿汤加减方对慢性光化性皮炎(chronic actinic dermatitis，CAD)的临床疗效，以及对患者外周血T细胞亚群及细胞因子水平的影响。[方法] 搜集2020年1月至2021年6月杭州市第三人民医院确诊的CAD患者60例，随机分为对照组和治疗组，每组各30例。对照组外用甘草油，治疗组在此基础上口服青蒿汤加减方，连续治疗4周。以瘙痒症状、皮损面积以及形态评分对临床疗效进行评价，并比较外周血总T淋巴细胞(CD3+ T细胞)、辅助性T淋巴细胞(CD3+CD4+ T细胞)、细胞毒性T淋巴细胞(CD3+CD8+ T细胞)、CD3+CD4+/CD3+CD8+T细胞比例，白细胞介素-17(interleukin-17，IL-17)、白细胞介素-22(interleukin-22，IL-22)及可溶性凋亡相关因子(soluble factor related apoptosis，sFas)及sFas配体(sFas ligand，sFasL)水平差异。[结果] 对照组和治疗组的瘙痒程度、皮损面积以及形态评分较治疗前均显著改善(P＜0.01)，临床评分较治疗前显著下降(P＜0.01)。对照组临床有效率73.33%，治疗组临床有效率93.33%，差异有统计学意义(P＜0.01)。与治疗前比较，治疗后两组患者外周血CD3+CD8+T细胞比例以及IL-22、sFas、sFasL水平显著降低(P＜0.01)，CD3+CD4+T细胞水平，CD3+CD4+/CD3+CD8+T细胞比例及IL-17水平显著升高(P＜0.01)。与对照组比较，治疗后治疗组患者的瘙痒程度和皮损面积改善更为显著(P＜0.01)，皮损部位的红斑、抓痕血痂以及肥厚程度显著改善(P＜0.05，P＜0.01)，皮损形态评分显著降低(P＜0.01)，CD3+CD4+ T细胞水平，CD3+CD4+/CD3+CD8+ T细胞比例及IL-17水平显著升高(P＜0.05，P＜0.01)，IL-22、sFas、sFasL水平显著降低(P＜0.01)。[结论] 青蒿汤加减方通过调节免疫功能，改善CAD患者症状，值得临床推广应用。 |
| 英文摘要: |
| [Objective] To investigate the clinical effect of modified Qinghao Decoction on patients with chronic actinic dermatitis(CAD) and its influence on peripheral blood T cell subsets and cytokine. [Methods] A total of 60 CAD patients diagnosed in Hangzhou Third People‘s Hospital from January 2020 to June 2021 were randomly divided into control group and treatment group， with 30 cases in each group. The control group received licorice oil externally， and the treatment group received modified Qinghao Decoction orally on this basis， for continuous 4-week treatment. Itching symptoms， skin lesion area and scores were used to evaluate the clinical efficacy， and differences of the levels of total T lymphocytes(CD3+ T lymphocytes)， helper T lymphocytes(CD3+CD4+ T lymphocytes)， cytotoxic T lymphocytes(CD3+CD8+ T lymphocytes)， ratio of CD3+CD4+/CD3+CD8+ T lymphocytes， and levels of interleukin-17(IL-17)， interleukin-22(IL-22) and soluble factor related apoptosis(sFas) and sFas ligand(sFasL) were compared. [Results] The pruritus， skin lesion area and morphological scores were significantly improved in control group and treatment group compared with those before treatment(P＜0.01)， and the clinical scores were significantly decreased in two groups compared with before treatment(P＜0.01). The clinical effective rate was 73.33% in control group and 93.33% in treatment group， with a statistically significant difference(P＜0.01). The levels of CD3+CD8+ T cells and IL-22， sFas， and sFasL of two groups were significantly lower than before treatment(P＜0.01)， and the level of CD3+CD4+ T cell， and ratio of CD3+CD4+/CD3+CD8+ T cell and IL-17 were significantly higher than before(P＜0.01). Compared with control group after treatment， the pruritus and area of skin lesions significantly relieved in treatment group(P＜0.01)， the erythema， blood scab and hypertrophy at the skin lesions were significantly relieved(P＜0.05，P＜0.01)， skin lesion morphology score was significantly decreased(P＜0.01)， the level of CD3+CD4+ T cell and IL-17， the ratios of CD3+CD4+/CD3+CD8+ T cell were significantly increased(P＜0.05，P＜0.01)， and the levels of IL-22， sFas and sFasL were significantly decreased(P＜0.01). [Conclusion] The modified Qinghao Decoction relieves symptoms of CAD patients through immunomodulatory， and it is worthy to clinical apply. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |